Yorvipath

News

AstraZeneca may struggle to differentiate eneboparatide, a hypoparathyroidism drug from its $800m takeover of Amolyt, from Ascendis' rival Yorvipath.

News

After turning it down a year ago, the FDA has cleared once-daily injectable Yorvipath for hypoparathyroidism from Ascendis Pharma.

News

A survey has shown that UK doctors think AI can help them save time and expand their capacity to care for patients, but training is lacking.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.